Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Lung Cancer | Research To Practice

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Lung Cancer

January 25, 2018, San Francisco, CA

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Lung Cancer

Please note that slides are for review only and not to be repurposed or published.

Introduction:
Dr Neil Love

MODULE 1:
Emerging Research Data with and Potential Clinical Role of Immune Checkpoint Inhibitors in the Management of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) — Dr Spigel

MODULE 2:
Identification and Management of Immune-Mediated and Other Toxicities Associated with Checkpoint Inhibitors; Relative Contraindications for Patients with Existing Autoimmune Disease — Dr Wakelee

MODULE 3:
Integration of Anti-PD-1/PD-L1 Antibodies into Current Treatment Algorithms for Patients with Metastatic NSCLC — Dr Langer

MODULE 4:
Novel Immunotherapeutic Approaches, Including Combination Strategies; Checkpoint Inhibition in Small Cell Lung Cancer (SCLC) — Dr Hellmann

Live Poll Results
Download